Vitreous biomarkers in diabetic retinopathy: a systematic review and meta-analysis.

[1]  C. Napoli,et al.  Effects of nitric oxide on cell proliferation: novel insights. , 2013, Journal of the American College of Cardiology.

[2]  Paul A. Yates,et al.  Pericytes Derived from Adipose-Derived Stem Cells Protect against Retinal Vasculopathy , 2013, PloS one.

[3]  N. Elsherbiny,et al.  Adenosine receptors: new therapeutic targets for inflammation in diabetic nephropathy. , 2013, Inflammation & allergy drug targets.

[4]  V. Haurigot,et al.  Long-Term Retinal PEDF Overexpression Prevents Neovascularization in a Murine Adult Model of Retinopathy , 2012, PloS one.

[5]  A. Loukas,et al.  Elevated Plasma IL-6 Associates with Increased Risk of Advanced Fibrosis and Cholangiocarcinoma in Individuals Infected by Opisthorchis viverrini , 2012, PLoS neglected tropical diseases.

[6]  P. Connell,et al.  Circulating biomarkers of diabetic retinopathy: a systematic review and meta-analysis , 2012 .

[7]  B. Klein,et al.  Global Prevalence and Major Risk Factors of Diabetic Retinopathy , 2012, Diabetes Care.

[8]  G. Bruno,et al.  Protective Role of Cannabinoid Receptor Type 2 in a Mouse Model of Diabetic Nephropathy , 2011, Diabetes.

[9]  Jian-xing Ma,et al.  A PEDF-Derived Peptide Inhibits Retinal Neovascularization and Blocks Mobilization of Bone Marrow-Derived Endothelial Progenitor Cells , 2011, Experimental diabetes research.

[10]  Qian Wang,et al.  Long-term Treatment with Suberythropoietic Epo is Vaso- and Neuroprotective in Experimental Diabetic Retinopathy , 2011, Cellular Physiology and Biochemistry.

[11]  A. Ergul.  Endothelin-1 and diabetic complications: focus on the vasculature. , 2011, Pharmacological research.

[12]  J. Scheller,et al.  The pro- and anti-inflammatory properties of the cytokine interleukin-6. , 2011, Biochimica et biophysica acta.

[13]  C. Romagnoli,et al.  Erythropoietin and retinopathy of prematurity. , 2011, Early human development.

[14]  F. Falcão-Reis,et al.  Arterial Thromboembolic Events in Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Bevacizumab or Ranibizumab , 2011, Ophthalmologica.

[15]  Yang Hu,et al.  Overexpression of pigment epithelium-derived factor inhibits retinal inflammation and neovascularization. , 2011, The American journal of pathology.

[16]  John Vontas,et al.  A Simple Colorimetric Assay for Specific Detection of Glutathione-S Transferase Activity Associated with DDT Resistance in Mosquitoes , 2010, PLoS neglected tropical diseases.

[17]  A. Schachat,et al.  A review of clinical trials of anti-VEGF agents for diabetic retinopathy , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[18]  W. Eldred,et al.  Increased neuronal nitric oxide synthase activity in retinal neurons in early diabetic retinopathy , 2009, Molecular vision.

[19]  M. Nagarkatti,et al.  Cannabinoids as novel anti-inflammatory drugs. , 2009, Future medicinal chemistry.

[20]  B. Bozkurt,et al.  Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness , 2009, Molecular vision.

[21]  A. Joussen,et al.  TNF-α mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations , 2009, Molecular vision.

[22]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[23]  M. Saint-Geniez,et al.  TGF-β Is Required for Vascular Barrier Function, Endothelial Survival and Homeostasis of the Adult Microvasculature , 2009, PloS one.

[24]  R. Klein,et al.  Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. , 2008, Archives of ophthalmology.

[25]  James P. Boyle,et al.  Projection of Diabetic Retinopathy and Other Major Eye Disease Cases AMong People with Diabetes: United States 2005-2050 , 2008 .

[26]  A. Barber,et al.  Retinal ganglion cells in diabetes , 2008, The Journal of physiology.

[27]  R. Simó,et al.  Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy , 2008, Diabetologia.

[28]  A. Ergul,et al.  Evidence for Vasculoprotective Effects of ETB Receptors in Resistance Artery Remodeling in Diabetes , 2007, Diabetes.

[29]  P. Dijke,et al.  Extracellular control of TGFβ signalling in vascular development and disease , 2007, Nature Reviews Molecular Cell Biology.

[30]  R. Avery,et al.  Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy , 2007, British Journal of Ophthalmology.

[31]  F. Kabbinavar,et al.  Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. , 2007, Journal of the National Cancer Institute.

[32]  M. Maia,et al.  Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES) , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[33]  Po-Len Liu,et al.  High Glucose Impairs Early and Late Endothelial Progenitor Cells by Modifying Nitric Oxide–Related but Not Oxidative Stress–Mediated Mechanisms , 2007, Diabetes.

[34]  Raghu Kacker,et al.  Random-effects model for meta-analysis of clinical trials: an update. , 2007, Contemporary clinical trials.

[35]  P. Kaiser.  Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. , 2006, American journal of ophthalmology.

[36]  C. Mailhos,et al.  Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. , 2006, The American journal of pathology.

[37]  Robert B. DiMartino.  Review of Ophthalmology , 2006 .

[38]  S. Masuda,et al.  Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. , 2005, The New England journal of medicine.

[39]  G. Gurtner,et al.  Human Endothelial Progenitor Cells From Type II Diabetics Exhibit Impaired Proliferation, Adhesion, and Incorporation Into Vascular Structures , 2002, Circulation.

[40]  M. Yanagisawa,et al.  Vascular Endothelin-B Receptor System In Vivo Plays a Favorable Inhibitory Role in Vascular Remodeling After Injury Revealed by Endothelin-B Receptor–Knockout Mice , 2002, Circulation.

[41]  P. Campochiaro,et al.  AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. , 2002, Investigative ophthalmology & visual science.

[42]  M. Boulton,et al.  The pathogenesis of diabetic retinopathy: old concepts and new questions , 2002, Eye.

[43]  R. Ali,et al.  Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1 , 2002, Gene Therapy.

[44]  G. Yancopoulos,et al.  VEGF-initiated blood-retinal barrier breakdown in early diabetes. , 2001, Investigative ophthalmology & visual science.

[45]  C. Cooper,et al.  Nitric oxide synthases: structure, function and inhibition. , 2001, The Biochemical journal.

[46]  A. Albert,et al.  Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. , 2001, Diabetes care.

[47]  Stephen J. Aldington,et al.  UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis , 2001, Diabetologia.

[48]  N. Bouck,et al.  Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[49]  K. Hirschi,et al.  PDGF, TGF-β, and Heterotypic Cell–Cell Interactions Mediate Endothelial Cell–induced Recruitment of 10T1/2 Cells and Their Differentiation to a Smooth Muscle Fate , 1998, The Journal of cell biology.

[50]  M. Tarnawski,et al.  Increased blood–brain barrier permeability and endothelial abnormalities induced by vascular endothelial growth factor , 1998, Journal of neurocytology.

[51]  M. Webb,et al.  Inhibitors of endothelin , 1997, Medicinal research reviews.

[52]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[53]  W. Jelkmann.  Erythropoietin: structure, control of production, and function. , 1992, Physiological reviews.

[54]  Y. Hattori,et al.  Effect of glucose and insulin on immunoreactive endothelin-1 release from cultured porcine aortic endothelial cells. , 1991, Metabolism: clinical and experimental.

[55]  K. Ohnaka,et al.  Enhanced secretion of endothelin‐1 by elevated glucose levels from cultured bovine aortic endothelial cells , 1990, FEBS letters.

[56]  J. Shaw,et al.  Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.

[57]  F. Ovalle.  10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes , 2009 .

[58]  P. Connell,et al.  Elevated glucose attenuates agonist- and flow-stimulated endothelial nitric oxide synthase activity in microvascular retinal endothelial cells. , 2007, Endothelium : journal of endothelial cell research.

[59]  M. Wojtukiewicz,et al.  Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. , 2003, Roczniki Akademii Medycznej w Bialymstoku.

[60]  Lois E. H. Smith,et al.  Oxygen-induced retinopathy in the mouse. , 1994, Investigative ophthalmology & visual science.

[61]  H. Lodish.  Molecular Cell Biology , 1986 .